Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

  1. OncologyPRO
  2. Meeting Resources
  3. ESMO 2018 Congress

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

4577 - MONITOR VII – Treatment Strategies of Low grade Ovarian Carcinomas – A German survey of the Charité – Berlin and Kliniken Essen Mitte with support of the study groups NOGGO and AGO

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Topics

Therapy

Tumour Site

Ovarian Cancer

Presenters

Sara Alavi

Citation

Annals of Oncology (2018) 29 (suppl_8): viii332-viii358. 10.1093/annonc/mdy285

Authors

S. Alavi1, P. Harter2, R. Richter3, M. Keller4, G. Oskay-Özcelik1, A. Mustea5, B. Schmalfeldt6, P. Wimberger7, F. Trillsch8, S. Mahner8, M. Klar9, U. Wagner10, R. Chekerov1, A. du Bois2, J. Sehouli1

Author affiliations

  • 1 Department Of Gynecology And Center For Oncological Surgery And European Competence Center For Ovarian Cancer, Charité Medical University, 13353 - Berlin/DE
  • 2 Gynecology & Gynecologic Oncology, Kliniken Essen Mitte Evang. Huyssens-Stiftung, 45136 - Essen/DE
  • 3 Department Of Gynecology, European Competence Center For Ovarian cancer, Charité - Universitätsmedizin Berlin, 13353 - Berlin/DE
  • 4 Noggo, North-Eastern German Society of Gynecological Oncology, 13353 - Berlin/DE
  • 5 Department Of Gynecology And Obstetrics, University Medicine Greifswald, 17475 - Greifswald/DE
  • 6 Gynaecology, University of Medical Center Hamburg-Eppendorf, 20246 - Hamburg/DE
  • 7 Department Of Gynecology And Obstetrics, Universitätsklinikum Dresden, 01307 - Dresden/DE
  • 8 Gynaecology, AGO Study Group & University of Munich, 81377 - München/DE
  • 9 Department Of Obstetrics And Gynecology, University Clinics of Freiburg, 79106 - Freiburg/DE
  • 10 Klinik Für Gynäkologie, Gyn. Endokrinologie Und Onkologie, University of Gießen and Marburg GmbH Site Marburg, 34043 - Marburg/DE

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Login

Abstract 4577

Background

Low grade serous carcinomas (LGSC), accounting for approximately 10% of the ovarian tumors, are associated with a better prognosis compared to high-grade serous carcinomas (HGSC). Nevertheless, we are confronted with a challenging treatment, since the median age at diagnosis is younger (55.5 years versus 62.6 years), standard platinum-based chemotherapy is less effective and most importantly, it has still not been as well studied as HGSC. The aim of this survey was to identify the current treatment strategies in Germany.

Methods

An anonymous, digital multiple-choice questionnaire, including 38 questions, was developed and provided to gynaecologists, gynaecologic oncologists and oncologists via Internet.

Results

From December 2017 to January 2018, a total of 180 participants took part in the survey (28% head physicians; 46% senior physicians). The median age was 49 years. 53% stated to have more than 15 years of experience in the treatment of cancer patients. No significant difference was seen in the extent of surgery between HGSC and LGSC (answered by 45%). While 88% stated to perform lymphonodectomy (LNE) for diagnostic and prognostic reasons, 69% used LNE as a decision-making tool for adjuvant therapy (answered by 47%). The most important factors for the indication of chemotherapy (answered by 47%) were comorbidities (92%), residual tumor (79%) and tumor histology (77%). While 43% did not consider antihormonal therapy as a treatment option, 39% stated to indicate a therapy with PARP-inhibitors (answered by 47%).

Conclusions

The results of this study underline the uncertainty in the treatment of LGSC. The implementation of own treatment standards and a prospective register for patients with LGSC is necessary and planed.

Clinical trial identification

Legal entity responsible for the study

North-Eastern German Society of Gynecological Oncology (NOGGO), Berlin, Germany.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

B. Schmalfeldt: Advisor: Roche, Astra Zeneca, Novartis, Tesoro Clovis; Travel support: Roche, AstraZeneca; Research support: MSD, Roche, AstraZeneca. A. du Bois: Advisory board: AstraZeneca, Roche, Pharmamar, Tesaro. All other authors have declared no conflicts of interest.

Resources from the same session

5671 - The landscape of NTRK fusions in Chinese solid tumor patients

Presenter: Qi Ling

Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Resources:

Abstract

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.